Welcome to our dedicated page for MASTEC SEC filings (Ticker: MTZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MASTEC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MASTEC's regulatory disclosures and financial reporting.
MasTec, Inc. (MTZ) – Form 144 filing
An unidentified holder has notified the SEC of a planned sale of 20,000 common shares on or about 04 Aug 2025. At the implied reference price, the deal is worth $3.6 million (≈ $180 per share). The stock was acquired via employee stock-option exercises on 14 Mar 2021 (8,862 sh) and 19 Mar 2023 (18,374 sh).
- Total shares outstanding: 78,907,954; proposed sale equals ≈ 0.03 % of the float—an immaterial amount in liquidity terms.
- Broker: Merrill Lynch; execution venue: NYSE.
- No sales by this holder in the previous three months.
- Standard representation states the seller knows of no undisclosed material adverse information.
The notice signals a routine insider transaction with no dilution and limited market impact, though investors may read it as a modest sentiment check.
MasTec (NYSE:MTZ) amended and restated its 2021 credit agreement, replacing it with a $1.9 billion revolving facility and simultaneously executed a $600 million unsecured term loan.
- Revolver maturity extended to five years; prior $328 million term loans retired.
- Key covenants eased—no minimum interest-coverage test and fewer limits on dividends or share repurchases.
- Pricing set at Term SOFR + 1.125%–1.625% (or Base Rate + 0.125%–0.625%), scaled to leverage and credit rating.
- New term loan matures in three years, carries no amortization and requires a max 3.5× leverage (temporarily 4.0× after qualifying acquisitions).
Proceeds will repay $277.5 million of legacy debt; balance supports general corporate purposes. Overall, the package markedly increases liquidity and capital-allocation flexibility while modestly raising gross debt.